{"id":2,"date":"2024-04-03T11:18:44","date_gmt":"2024-04-03T11:18:44","guid":{"rendered":"https:\/\/magazine.lillianbgruss.com\/blog\/?page_id=2"},"modified":"2024-04-16T22:44:03","modified_gmt":"2024-04-16T22:44:03","slug":"sample-page","status":"publish","type":"page","link":"https:\/\/magazine.lillianbgruss.com\/blog\/","title":{"rendered":"The Role of the Federal Government in United States Drug Shortages"},"content":{"rendered":"\n<p class=\"has-small-font-size wp-block-paragraph\"><strong>Lily Gruss<\/strong> | April 12, 2024 | <a href=\"http:\/\/mariemcallister.org\/drugpolicy\/\">Drugs Aren\u2019t a Problem &amp; Other Lies the Government Tells You<\/a><\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized is-style-default\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"648\" src=\"https:\/\/magazine.lillianbgruss.com\/blog\/wp-content\/uploads\/2024\/04\/tablets-nutrient-additives-dietary-supplements-0d04fc-1024-e1712783366728.jpg\" alt=\"\" class=\"wp-image-19\" style=\"width:759px;height:auto\" srcset=\"https:\/\/magazine.lillianbgruss.com\/blog\/wp-content\/uploads\/2024\/04\/tablets-nutrient-additives-dietary-supplements-0d04fc-1024-e1712783366728.jpg 1024w, https:\/\/magazine.lillianbgruss.com\/blog\/wp-content\/uploads\/2024\/04\/tablets-nutrient-additives-dietary-supplements-0d04fc-1024-e1712783366728-300x190.jpg 300w, https:\/\/magazine.lillianbgruss.com\/blog\/wp-content\/uploads\/2024\/04\/tablets-nutrient-additives-dietary-supplements-0d04fc-1024-e1712783366728-768x486.jpg 768w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><figcaption class=\"wp-element-caption\">Photo From creativecommons.org<\/figcaption><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\" style=\"font-size:22px\"><strong>Introduction<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The issue of prescription drug shortages in the United States is, by all accounts, a glaring one. Pervasive to the lives of anyone relying on the United States healthcare system, drug shortage problems predictably put at risk anyone who needs very specific drugs for a health issue. Shortages of drugs are characterized by a lack of ability of suppliers to meet demands by consumers; this is often exacerbated by the fact that many drugs, including critical drugs to cancer treatment, have only one commercial supplier (Ventola). Even the United States, an undeniably wealthy country on the world stage, experienced shortages of over 300 drugs throughout 2023, as reported by the American Society of Health-System Pharmacists. Predictably, as the U.S. healthcare system is relied upon by its residents, drug shortages inflict detrimental effects upon the health of the public, increasing the frequency of wrongful use of different prescription drugs. Drug shortages are caused by many factors, some of the most notable among them difficulties with interaction between governments and drug companies; increased governmental attention and regulation should be implemented in order to reduce drug shortages and their effects, including economic strain on hospitals and, most notably, health risks to consumers.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\" style=\"font-size:22px\"><strong>Whose Fault?<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">It is difficult to direct the blame for drug shortages in a way that is productive. The healthcare system in the United States, specifically the pharmaceuticals industry, is a collage of moving parts. As such, the production of drugs has implications in many different spheres. Though pharmaceuticals are generally produced by private companies, there is extensive interaction between these companies and domestic as well as foreign governments. This is due to the need for raw materials used for medicines; this is especially true for United States-based pharmaceuticals suppliers, as \u201cit is estimated that 80% of the raw materials in the pharmaceuticals sold in the U.S. are imported from abroad\u201d (Ventola). In addition, government agencies such as the Food and Drug Administration play an enhanced role in the healthcare system, providing regulations for the production of widely-distributed drugs; the unity of governmental action with the actions of private corporations in this process make it difficult to pinpoint blame for pharmaceutical shortages; a multitude of factors combine to exacerbate regulatory and jurisdictional issues (Yu, Shukar, et. al.).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">One significant ongoing lapse in communication between U.S. federal government and pharmaceutical companies that has been blamed for drug shortages is the lack of stringent guidelines obliging companies to communicate with regulatory agencies upon planning to cease production of a specific drug. When a drug becomes unprofitable to its production company, the company will often stop producing it. Because a halt in production of a specific drug is extremely pertinent information to the consumers of that drug, existing guidelines require companies to warn the Food and Drug Administration of a seizure in production six months before it goes into effect so a suitable replacement can be found; however, this policy is only involuntary if the drug in question is deemed \u201cmedically necessary\u201d (Ventola). Because the necessity of a drug is difficult to quantify, the lack of exact guidelines for which types of drugs require notification of the FDA leads to situations in which a halt in production of a drug is never reported and other sources the drug not explored before those who rely on it can no longer obtain it. Agencies such as the FDA and the CDC have themselves been blamed for shortages, as an increase in regulatory policies on companies predictably leads to shortages when companies are no longer able to comply with such regulations. In the United States specifically, many drug shortages are attributed to necessary reevaluations of drugs according to new FDA guidelines (Yu, Shukar, et al.). This issue illuminates the difficult relations between pharmaceutical companies and regulatory agencies: strict manufacturing regulations are not functional unless there is effort from the corporations in question to materially increase the quality of their product.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As mentioned, the necessity of raw materials only available through international trade further complicates the production of drugs: \u201ceven if there are multiple manufacturers of a drug, there may be only one producer of a raw material that is used in producing that drug\u201d (Ventola). Unlike synthetic materials which can simply be purchased from another producer in the event of a shortage from the first, the depletion of naturally-occuring raw materials is not easily fixed. Obtention of raw materials as an issue in drug production is further exacerbated by the ever-shifting relations between the United States and other nations; in particular, China produces more critical raw materials (CRMs) than any other nation (CBS). The tumultuous relationship between China and the United States is volatile, and a perceived slight from either can cause drastic supply chain issues for medicines made using materials imported from China.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\" style=\"font-size:22px\"><strong>Who Pays the Price?<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Due to the high degree of interaction of the U.S. healthcare system with the economy as well as governmental policies, shortages of prescription drugs cause a diverse myriad of effects not confined to the clinical. Hospitals and other institutions providing healthcare are particularly drastically affected by drug shortages with regards to economic concerns. Shortages of medications commonly used by healthcare practitioners necessitates the use of alternatives to said medications (Phuong). However, this is extremely disadvantageous to institutions such as hospitals, as alternatives to critical drugs are often expensive, leading to much higher costs; further costs to medical institutions are added with the increase in labor hours required of those who must learn to administer drugs they are unfamiliar with once the standard drugs are in shortage (Ventola). The underfunding of hospitals is a chronic problem; as reported by the Trust for America\u2019s Health, less than 3% of the annual healthcare budget provided by the United States government is used for public health purposes. Drug shortages further inhibit the ability of healthcare systems to provide adequate care in ways beyond inability for direct clinical administration.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The most urgent issue caused by shortages of widely-used pharmaceuticals, though, is the direct effect on consumers. As reported by the Health Policy Institute of Georgetown University, 66% of adults in the United States rely on prescription medication. It is no wonder, then, that shortages of over 300 common drugs take a detrimental effect on consumers. If hospitals cannot maintain the repeated purchase of expensive alternatives to other drugs, dangerous outcomes such as the rationing of life-saving drugs can occur; in a 2023 article for Reuters, Khushi Mandowara reports just this. One of the groups most intensely affected by drug shortages is those suffering from cancer. The White House reported on September 12, 2023, that 15 life-saving oncological drugs were undergoing shortages, three of them extremely widely-used and critical for cancer treatment. The American Society of Health-System Pharmacists reports that one such drug, Cytarabine, used specifically to treat leukemia, has been in constant shortage for over 10 years; alternatives to Cytarabine are extremely scarce. As such, those with leukemia receiving treatment with this specific drug are in danger of losing it to a supply chain or manufacturing issue. Those relying on medications that do have available alternatives are not shielded from this issue either, as replacing one medication for another, seemingly with the same purpose, is not necessarily safe and can lead to dangerous side effects.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\" style=\"font-size:22px\"><strong>What Should be Done?<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">An entirely free market-based healthcare system is dangerous to consumers. Medicare, the United States\u2019 governmental healthcare insurance program, was implemented in the country in response to the failures of the insurance industry to help those over 65 due to their status of retirement. The Center for Medicare Advocacy reports that, as of March 2023, the monumental sum of \u200b\u200b65,748,297 Americans, or 20%, were recipients of Medicare. Medicare\u2019s efficacy at assisting those failed by the medical industry is evidence that government intervention in free-market healthcare systems has the ability to help those who have found themselves disadvantaged by it. Coupled with increased attention and response to their effects, governmental intervention in the causes of drug shortages, specifically issues related to the interaction of pharmaceutical companies and regulatory agencies, has the potential to mitigate how widespread and critical an issue drug shortages are. One clear policy path towards this goal is the implementation of stricter regulations regarding warnings to the FDA upon the seizure of drug production; if put into practice, this policy would likely drastically reduce the amount of hardship caused by seemingly unexpected shortages, allowing for increased time to discover and begin production on tested alternatives. In addition, reconsideration of the allocation of healthcare funding would reduce stress placed on hospitals caused by drug shortages.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\" style=\"font-size:22px\"><strong>Conclusion<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The causes and effects are not only varied but substantial. An issue such as this\u2013one that is so pertinent to the everyday lives of Americans\u2013should be at the forefront of the public and governmental imagination. However, there continues to be over 100 new drug shortages in the United States each year. The healthcare system is one of the most exceedingly relied-upon institutions in the nation; issues as large as the drug shortage epidemic should not be ignored nor responded to halfheartedly. The path to a more reliable structure of pharmaceutical provision begins with increased attention and regulation.&nbsp;<\/p>\n\n\n\n<div style=\"height:147px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"wp-block-paragraph\" style=\"font-size:22px\"><strong>Works Cited<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\" style=\"font-size:15px\">American Society of Health-System Pharmacists. \u201cDrug Shortage Detail: Cytarabine Injection.\u201d <em>ASHP<\/em>, 2023, <a href=\"https:\/\/www.ashp.org\/drug-shortages\/current-shortages\/drug-shortage-detail.aspx?id=770&amp;loginreturnUrl=SSOCheckOnly\">https:\/\/www.ashp.org\/drug-shortages\/current-shortages\/drug-shortage-detail.aspx?id=770&amp;loginreturnUrl=SSOCheckOnly<\/a>.&nbsp; Accessed 15 March 2024.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\" style=\"font-size:15px\">American Society of Health-System Pharmacists. \u201cDrug Shortages Statistics.\u201d <em>ASHP<\/em>, 2023, <a href=\"https:\/\/www.ashp.org\/drug-shortages\/shortage-resources\/drug-shortages-statistics\">https:\/\/www.ashp.org\/drug-shortages\/shortage-resources\/drug-shortages-statistics<\/a>.&nbsp; Accessed 12 March 2024.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\" style=\"font-size:15px\">Center for Medicare Advocacy. \u201cMedicare Enrollment Numbers.\u201d <em>Center for Medicare Advocacy<\/em>, 29 June 2023, <a href=\"https:\/\/medicareadvocacy.org\/medicare-enrollment-numbers\/\">https:\/\/medicareadvocacy.org\/medicare-enrollment-numbers\/<\/a>.&nbsp; Accessed 15 March 2024.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\" style=\"font-size:15px\">Centraal Bureau voor de Statistiek. \u201cChina top supplier of products containing critical raw materials.\u201d <em>CBS<\/em>, 28 November 2023, <a href=\"https:\/\/www.cbs.nl\/en-gb\/news\/2023\/48\/china-top-supplier-of-products-containing-critical-raw-materials\">https:\/\/www.cbs.nl\/en-gb\/news\/2023\/48\/china-top-supplier-of-products-containing-critical-raw-materials<\/a>.&nbsp; Accessed 18 March 2024.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\" style=\"font-size:15px\">Georgetown University. \u201cPrescription Drugs | Health Policy Institute | Georgetown University.\u201d <em>Health Policy Institute<\/em>, <a href=\"https:\/\/hpi.georgetown.edu\/rxdrugs\/#\">https:\/\/hpi.georgetown.edu\/rxdrugs\/#<\/a>.&nbsp; Accessed 18 March 2024.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\" style=\"font-size:15px\">Mandowara, Khushi. \u201cU.S. hospital pharmacists ration drugs as shortages persist \u2013 survey.\u201d <em>Reuters<\/em>, 10 August 2023, <a href=\"https:\/\/www.reuters.com\/world\/us\/us-hospital-pharmacists-ration-drugs-shortages-persist-survey-2023-08-10\/\">https:\/\/www.reuters.com\/world\/us\/us-hospital-pharmacists-ration-drugs-shortages-persist-survey-2023-08-10\/<\/a>.&nbsp; Accessed 15 March 2024.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\" style=\"font-size:15px\">National Academy of Social Insurance. \u201cThe History of Medicare.\u201d <em>National Academy of Social Insurance<\/em>, <a href=\"https:\/\/www.nasi.org\/learn\/medicare\/the-history-of-medicare\/\">https:\/\/www.nasi.org\/learn\/medicare\/the-history-of-medicare\/<\/a>.&nbsp; Accessed 15 March 2024.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\" style=\"font-size:15px\">Phuong, Jonathan M. \u201cThe impacts of medication shortages on patient outcomes: A scoping review.\u201d <em>NCBI<\/em>, 3 May 2019, <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6499468\/\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6499468\/<\/a>.&nbsp; Accessed 18 March 2024.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\" style=\"font-size:15px\">Trust for America\u2019s Health. \u201cThe Impact of Chronic Underfunding on America\u2019s Public Health System: Trends, Risks, and Recommendations, 2020 \u2013 TFAH.\u201d <em>Trust for America\u2019s Health<\/em>, 2020, <a href=\"https:\/\/www.tfah.org\/report-details\/publichealthfunding2020\/\">https:\/\/www.tfah.org\/report-details\/publichealthfunding2020\/<\/a>.&nbsp; Accessed 17 March 2024.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\" style=\"font-size:15px\">Ventola, Lee. \u201cThe Drug Shortage Crisis in the United States: Causes, Impact, and Management Strategies.\u201d <em>NCBI<\/em>, 2011, <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3278171\/\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3278171\/<\/a>.&nbsp; Accessed 14 March 2024.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\" style=\"font-size:15px\">The White House. \u201cStrengthening the supply chain for cancer drugs | OSTP.\u201d <em>The White House<\/em>, 13 September 2023, <a href=\"https:\/\/www.whitehouse.gov\/ostp\/news-updates\/2023\/09\/12\/strengthening-the-supply-chain-for-cancer-drugs\/\">https:\/\/www.whitehouse.gov\/ostp\/news-updates\/2023\/09\/12\/strengthening-the-supply-chain-for-cancer-drugs\/<\/a>.&nbsp; Accessed 20 March 2024.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\" style=\"font-size:15px\">Yu, Shukar, et al. \u201cDrug Shortage: Causes, Impact, and Mitigation Strategies.\u201d <em>Frontiers<\/em>, 2021, <a href=\"https:\/\/www.frontiersin.org\/journals\/pharmacology\/articles\/10.3389\/fphar.2021.693426\/full\">https:\/\/www.frontiersin.org\/journals\/pharmacology\/articles\/10.3389\/fphar.2021.693426\/full<\/a>.&nbsp; Accessed 15 March 2024.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lily Gruss | April 12, 2024 | Drugs Aren\u2019t a Problem &amp; Other Lies the Government Tells You Introduction The issue of prescription drug shortages in the United States is, by all accounts, a glaring one. Pervasive to the lives of anyone relying on the United States healthcare system, drug shortage problems predictably put at&hellip; <\/p>\n<div class=\"readmore-wrapper\"><a href=\"https:\/\/magazine.lillianbgruss.com\/blog\/\" class=\"more-link\">Read More<\/a><\/div>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"open","template":"","meta":{"footnotes":""},"class_list":["post-2","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/magazine.lillianbgruss.com\/blog\/wp-json\/wp\/v2\/pages\/2","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/magazine.lillianbgruss.com\/blog\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/magazine.lillianbgruss.com\/blog\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/magazine.lillianbgruss.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/magazine.lillianbgruss.com\/blog\/wp-json\/wp\/v2\/comments?post=2"}],"version-history":[{"count":12,"href":"https:\/\/magazine.lillianbgruss.com\/blog\/wp-json\/wp\/v2\/pages\/2\/revisions"}],"predecessor-version":[{"id":40,"href":"https:\/\/magazine.lillianbgruss.com\/blog\/wp-json\/wp\/v2\/pages\/2\/revisions\/40"}],"wp:attachment":[{"href":"https:\/\/magazine.lillianbgruss.com\/blog\/wp-json\/wp\/v2\/media?parent=2"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}